Core Viewpoint - The company anticipates a decrease in demand for its animal health products due to a slowdown in China's livestock industry starting from the third quarter of 2025, yet expects a significant increase in overall profit for the fiscal year 2025 [1] Group 1: Financial Performance - The company projects a shareholder's net profit of approximately $32 million for the fiscal year ending December 31, 2025, compared to $11.2 million for the fiscal year ending December 31, 2024 [1] - The growth in profit is primarily attributed to a substantial increase in revenue, reflecting the successful implementation of a key strategy focused on developing large customer sales [1] Group 2: Revenue Expectations - The company's quarterly revenue for the three months ending December 31, 2025, is expected to remain at a similar level to that of the three months ending September 30, 2025 [1]

Group 1 - The company expects to achieve an unaudited consolidated profit attributable to shareholders of approximately $23.5 million for the nine months ending September 30, 2025, compared to $4.3 million for the same period ending September 30, 2024, indicating significant profit growth driven by a substantial increase in revenue [1] - The profit growth is attributed to the successful implementation of key strategies focused on developing large customer sales [1] - However, due to a slowdown in China's livestock industry, the demand for the company's animal health pharmaceutical products is expected to decrease starting from the third quarter of 2025 [1] Group 2 - The company anticipates that its unaudited quarterly profit attributable to shareholders for the three months ending September 30, 2025, will decline to approximately $6.5 million, down from $9.3 million for the three months ending June 30, 2025 [1]